A Medical Device Daily

Inbone (Berkely, California) and its founder Mark Reiley, MD, chief medical officer reported the submission of its 25th patent application to support the companies expanding intellectual property portfolio.

The newest products in the extremity market are the Inbone Total Ankle and the Inbone Fusion System, both of which are FDA 510(k) approved.

Reiley is most widely known for developing the Balloon Kyphoplasty technique, used to repair osteoporotic and myelomatous spinal compression fractures.

Reiley is also the developer of the Archus Total Facet Arthroplasty System, a spinal implant designed to treat spinal stenosis. This spinal implant is currently under FDA study, and so far has shown the ability to treat both leg and back pain.

In addition, Reiley is currently working on seven additional inventions, which will be readied for market over the next several years. These efforts include enhancements to the current Inbone product line focused on treatment of foot and ankle disorders. It is expected that Reiley’s new designs will focus in orthopedic markets including the hand/wrist and orthopedic solutions for the circulatory system.

Inbone Technologies is a medical innovator of surgical treatments for foot and ankle arthritis.

RegeneRx Biopharmaceuticals (Bethesda, Maryland)reported that a U.S. patent related to wound healing has been issued to the company by the U.S. Patent and Trademark Office. The patent claims are based on a significant body of data developed by the National Institutes of Health and include numerous claims relating to Thymosin beta 4 (T 4), its analogues, related compounds, fragments and other variants.

T 4’s wound healing properties are the subject of four RegeneRx-sponsored Phase 2 clinical trials in chronic pressure ulcers; venous stasis ulcers; epidermolysis bullosa, a difficult-to-heal skin blistering disease and orphan indication; and diabetic patients undergoing corneal surgery. The company is also sponsoring a Phase 1 clinical trial in healthy volunteers to assess the safety of its injectable formulation for use in heart attack patients.

RegeneRx is focused on the development of novel molecules to accelerate tissue and organ repair.